Coronary artery disease (CAD), which includes narrowing or even closing of the arteries of the heart and frequently leads to cardiac arrest, is a major cause of death worldwide. Regardless of the presence of treatments such as drug-eluting stents and cholesterol-lowering drugs– a new stent technology for local drug delivery– death from this condition is still common, and some patients seem resistant to treatment.
TGCV is an emerging cardiovascular condition characterized by scattered constricting coronary atherosclerosis with triglyceride (TG) deposition triggered by defective intracellular lipolysis. Follow-up coronary computed tomography angiography showed marked regression of atherosclerotic sores with luminal dilatation (left coronary artery shown as red line in upper panel A; right and left coronary arteries in upper panel B). Credit: 2022, Ken-ichi Hirano, Remarkable regression of diffuse coronary atherosclerosis in patients with triglyceride deposit cardiomyovasculopathy., European Heart Journal
” Almost 15 years ago we recognized a brand-new type of CAD called triglyceride deposit cardiomyovasculopathy (TGCV), in which the coronary arteries are occluded by triglyceride deposits produced by faulty intracellular breakdown of triglycerides in vascular smooth muscle cells,” says lead author of the research study Ken-ichi Hirano. “This system makes TGCV unique from classic cholesterol-induced atherosclerosis, and accounts for patients who are resistant to standard solutions for CAD.”
The researchers had actually established diagnostic requirements for TGCV, and revealed that this condition is particularly widespread in clients with diabetes mellitus and those who have actually undergone hemodialysis. In spite of the capability to identify this condition, nevertheless, an efficient treatment for these patients stayed evasive.
” Now we report a remarkable regression of scattered coronary atherosclerosis in two patients with TGCV,” states Ken-ichi Hirano. “Both had actually struggled with refractory chest pain and diabetes until diagnosis with TGCV, and subsequent dietary consumption of tricaprin resulted in sign relief.”
Coronary CT images with a color-coded display for case 1 (panel A) Color-coded short-axis CT images prior to (A) and after (on-treatment) (B) tricaprin treatment. The short-axis pictures of the left coronary anterior coming down artery are shown at every 0.2 mm: a, b, c, d, e, and f correspond to cross-sectional pictures of the second image. Credit: 2022, Ken-ichi Hirano, Remarkable regression of scattered coronary atherosclerosis in patients with triglyceride deposit cardiomyovasculopathy., European Heart Journal
Tricaprin is a commercially offered food supplement that promotes lipid breakdown by heart muscle cells. In addition to relieving these clients unpleasant and frustrating symptoms, tricaprin likewise led to impressive regression of the triglyceride accumulation in the blood vessels of the heart.
” While atherosclerosis regression following reduced serum lipid levels is well-described, this is the very first report of regression due to increased triglyceride lipolysis within cells, and as such is a conceptually unique treatment for coronary atherosclerosis,” says Ken-ichi Hirano.
Considered that not all patients react to current treatments for CAD, the findings from this study lead the way towards developing a multi-faceted approach to CAD treatment. The significant outcomes attained by administering an easily offered dietary supplement hold pledge for patients who would otherwise continue to suffer the devastating results of this illness.
Reference: “Remarkable regression of diffuse coronary atherosclerosis in patients with triglyceride deposit cardiomyovasculopathy” by Ken-ichi Hirano, Masahiro Higashi and Kenichi Nakajima, 30 December 2022, European Heart Journal.DOI: 10.1093/ eurheartj/ehac762.
The research study was funded by the Ministry of Health, Labour, and Welfare of Japan, and Nihon Medi-physics Co., Ltd
.
TGCV is an emerging cardiovascular disorder characterized by diffuse constricting coronary atherosclerosis with triglyceride (TG) deposition caused by faulty intracellular lipolysis. TGCV is an often-undiagnosed condition in patients who are resistant to standard therapies. Follow-up coronary computed tomography angiography showed marked regression of atherosclerotic lesions with luminal dilatation (left coronary artery revealed as red line in upper panel A; right and left coronary arteries in upper panel B). Credit: 2022, Ken-ichi Hirano, Remarkable regression of diffuse coronary atherosclerosis in patients with triglyceride deposit cardiomyovasculopathy., European Heart Journal
Credit: 2022, Ken-ichi Hirano, Remarkable regression of diffuse coronary atherosclerosis in patients with triglyceride deposit cardiomyovasculopathy., European Heart Journal
Triglyceride deposit cardiomyovasculopathy is a heart and capillary condition where plaque builds up in the arteries due to high levels of triglycerides in the blood. This accumulation can lead to symptoms such as chest pain and problem breathing, and can increase the risk of heart attack or stroke.
Osaka University researchers discover that taking tricaprin routinely in your diet causes a decrease in coronary artery plaque and an enhancement of signs for patients with triglyceride deposit cardiomyovasculopathy.
As children, our parents motivated us to take vitamins for growth and strength. Now, Japanese scientists have actually found that a specific supplement might even repair a broken heart.
In a study that was just recently released in the European Heart Journal, researchers from Osaka University discovered that a dietary supplement can significantly enhance cardiovascular disease symptoms in a subset of clients.
